31 results on '"Cappelli, Luca Vincenzo"'
Search Results
2. Endothelial cell–leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities
3. A case of familial donor-derived acute myeloid leukemia with underlying pre-leukemic mutations
4. Editorial: Novelties in acute myeloid leukemia: from biology to clinical applications.
5. BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study
6. DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern
7. S235: GENERATION AND APPLICATION OF A LIVING T-CELL LYMPHOMA PATIENT-DERIVED TUMOR XENOGRAFT BIOREPOSITORY
8. IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies
9. Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature
10. Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia
11. Metabolic and Immune Markers for Precise Monitoring of COVID-19 Severity and Treatment
12. A Predictive Endothelial-Leukemia Pre-Clinical Platform to Uncover Drug Vulnerabilities for Personalized Treatments
13. Selective STAT3 Degraders Dissect Peripheral T-Cell Lymphomas Vulnerabilities Empowering Personalized Regimens
14. Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia
15. Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma
16. TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia
17. Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression
18. A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries
19. Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
20. Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression.
21. DNMT3A and NPM1 Double Mutated AML Is a Phenomenon of the Younger Patient and Could Represent a New Entity
22. NPM1 Mutated AML Is Characterized By Pre-Leukemic Mutations and the Persistence and Acquisition of Co-Mutations in Molecular Remission Leads to Inferior Prognosis
23. TP53 Clonal and Subclonal Architecture in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment
24. Early Stage Follicular Lymphoma. Predictive Role of Minimal Residual Disease (MRD) and Impact of MRD-Driven Treatment with Radiotherapy and Rituximab on Clinical Outcome
25. DNMT3Amutations are over-represented in young adults with NPM1mutated AML and prompt a distinct co-mutational pattern
26. DNMT3Aand NPM1Double Mutated AML Is a Phenomenon of the Younger Patient and Could Represent a New Entity
27. NPM1Mutated AML Is Characterized By Pre-Leukemic Mutations and the Persistence and Acquisition of Co-Mutations in Molecular Remission Leads to Inferior Prognosis
28. TP53Clonal and Subclonal Architecture in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment
29. BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study.
30. A Case of Central Venous Catheter-Related Candida parapsilosis Fungemia Evolved to Disseminated Infection in a Neutropenic Patient with Blast Crisis of Chronic Myeloid Leukemia.
31. Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.